Pathogen Identification via mNGS Max (PIM Max)

PIM-Max utilizes mNGS technology, which can dual detect both DNA and RNA pathogens in a wide range of clinical samples such as BALF, blood, cerebrospinal fluid, sputum, pleural or peritoneal fluid, tissues, etc., and covers 26,270 pathogens at once, which is suitable for the diagnosis of emergency and severe infections, infections of unknown origin, infections of patients with immune deficiencies, infections of rare or neoplastic pathogens, and suspected mixed DNA and RNA infections.

1. Detection Scope

2. Technical Advantages

lDNA & RNA pathogen dual detection products, more cost-effective


lNew technology of double reverse enrichment to improve the sensitivity of RNA virus detection

PIM-Max is designed for the detection of RNA viruses with low load and easily interfered by gDNA and rRNA. PIM-Max successively adopts the double reverse enrichment of RNA viruses by gDNA digestion and rRNA suppressed probe technology, which effectively removes rRNA, ensures the performance of RNA viruses and improves the total positive rate of the diagnosis of mixed DNA & RNA pathogen infections.


lThe patented technology of molecular drug sensitivity phenotype pediction helps clinical precision treatment.


Relying on tens of thousands of bacterial genome sequencing data and the patented machine learning technology developed by GensKey, GenseqAMR is able to predict the drug sensitivity of 8 common drug-resistant bacteria, and the consistency rate of the prediction results with the culture sensitivity results is higher than 90%, which can provide the first time reference for the clinic to guide the drug usage.

3. Clinical Application Scenarios

Not for use in diagnostic procedures (except as specifically noted).